Tricuspid regurgitation surgery

Tricuspid Regurgitation Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Tricuspid Regurgitation from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Stages
History and Symptoms
Physical Examination
Laboratory Findings
Echocardiography
Chest X Ray
Electrocardiogram
Cardiac Stress Test
Cardiac MRI
Cardiac Catheterization
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical therapy
Surgery
Primary Prevention
Secondary Prevention
Case Studies
Case #1
Tricuspid regurgitation surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Tricuspid regurgitation surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA onTricuspid regurgitation surgery
CDC on Tricuspid regurgitation surgery
Tricuspid regurgitation surgery in the news
Blogs on Tricuspid regurgitation surgery
Directions to Hospitals Treating Tricuspid regurgitation
Risk calculators and risk factors for Tricuspid regurgitation surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Zand, M.D.[2] Rim Halaby, M.D. [3] Fatimo Biobaku M.B.B.S [4]

Overview

Pulmonary hypertension or myocardial disease are two factors that affect the treatment of secondary TR. The surgical approach is considered for selected patients with severe TR (stage C,D) at the time of left-sided valve lesions surgery and to prevent later development of severe TR in patients with progressive TR (Stage B). For selected patients with isolated TR (either primary TR or secondary TR attributable to annular dilation in the absence of pulmonary hypertension or dilated cardiomyopathy), surgical intervention is recommended. Mortality rate is high in patients undergone interventions for severe isolated TR due to end-organ damage. However, outcomes of patients with severe primary TR are poor with medical management. Earlier surgery for patients with severe isolated TR before the onset of severe RV dysfunction or end-organ damage is recommended.

Surgery

Indications for Surgery

Recommendations for intervention in tricuspid valve disease
Primary Tricuspid Regurgitation (Class I, Level of Evidence C):
❑Surgery is recommended in patients with severe primary tricuspid regurgitation undergoing left-sided valve surgery ❑Surgery is recommended in symptomatic patients with isolated severe primary tricuspid regurgitation without severe RV dysfunction
Primary Tricuspid Regurgitation (Class IIa, Level of Evidence C):
❑Surgery should be considered in patients with moderate primary tricuspid regurgitation undergoing left-sided valve surgery ❑Surgery should be considered in asymptomatic or mildly symptomatic patients with isolated severe primary tricuspid regurgitation and RV dilatation who are appropriate for surgery
Secondary Tricuspid Regurgitation (Class I, Level of Evidence B):
❑Surgery is recommended in patients with severe secondary tricuspid regurgitation undergoing left-sided valve surgery
Secondary Tricuspid Regurgitation (Class IIa, Level of Evidence B):
❑Surgery should be considered in patients with mild or moderate secondary tricuspid regurgitation with a dilated annulus (≥40 mm or >21 mm/m2 by 2D echocardiography) undergoing left-sided valve surgery ❑Surgery should be considered in patients with severe secondary tricuspid regurgitation (with or without previous left-sided surgery) who are symptomatic or have RV dilatation, in the absence of severe RV or LV dysfunction and severe pulmonary vascular disease/ pulmonary hypertension
Secondary Tricuspid Regurgitation (Class IIb, Level of Evidence C):
❑Transcatheter treatment of symptomatic secondary severe tricuspid regurgitation may be considered in inoperable patients

The above table adopted from 2021 ESC Guideline

Tricuspid regurgitation

Progressive TR (Stage B)

At time of left sided valve surgery

Severe TR (Stage C,D)

Annular dilation> 4 cm, or perior righ heart failure

Asymptomatic (Stage C)

At time of left sided valve surgery

Right heart failure (Stage D)

TV surgery (2a)

Primary TR with progressive RV dilation or systolic dysfunction

TV surgery (1)

TV surgery (2b)

Primary TR

Prior left sided valve surgery

Secondary TR

TV surgery (2a)

Absent of severe pulmonary hypertension or RV systolic dysfunction

Poor response to medical therapy

TV surgery (2b)

Annular dilation without pulmonary hypertension or left sided disease

TV surgery (2a)

Abbreviations: TR: Tricuspid Regurgitation; TV: Tricuspid valve; RV: Right ventricle

The above algorithm adapted from 2020 AHA Guideline

• Primary or secondary severe TR may not improve after treatment of the left-sided valve lesion and reduction of RV afterload.
• Re-operation for severe, isolated TR after left-sided valve surgery is associated with a perioperative mortality rate of 10% to 25%.
• Tricuspid valve repair will not increase the risks of surgery.
• Tricuspid valve repair is preferable to replacement due to lower operative risk, but replacement may be indicated if there is marked dilation of the annulus or intrinsic disease of the tricuspid leaflets.
• The risks and benefits of tricuspid valve operation should be carefully considered in the presence of severe RV systolic dysfunction or irreversible pulmonary hypertension because of the possibility of RV failure after the operation.
• If mild or moderate degrees of secondary TR are left uncorrected at the time of left-sided valve surgery, they may progress over time in approximately 25% of patients and result in reduced long-term functional outcome and survival.
• Risk factors for persistence or progression of TR include tricuspid annulus dilation (>40 mm diameter or 21 mm/m2 diameter indexed to body surface area on preoperative TTE measured at end-diastole; >70 mm diameter on direct intraoperative measurement of the intercomissural distance), degree of RV dysfunction or remodeling, leaflet tethering height, pulmonary artery hypertension, AF, and intra-annular RV pacemaker or implantable cardioverter-defibrillator leads.
• Studies showed the benefits of tricuspid repair at the time of mitral valve surgery for progressive TR (Stage B) with tricuspid annulus dilation.

• In patients with symptomatic severe primary TR, reduction of the regurgitant volume load by tricuspid valve surgery can decrease systemic venous and hepatic congestion and the need for diuretics.
• Patients with severe congestive hepatopathy may also benefit from surgery to prevent irreversible cirrhosis of the liver.
• Quality and duration of long-term survival are related to residual RV function.
• In patients with severe symptomatic primary TR from either device leads or endomyocardial biopsy, TR develops rapidly, and surgery can be performed before the onset of RV dysfunction.
• Correction of symptomatic severe primary TR (Stage D) in patients without left-sided valve disease would preferentially be performed before the onset of significant RV dysfunction or end-organ damage
• TR can develop in attribution with AF and annular dilation (a form of secondary TR).
• AF-related TR may represent greater basal dilation and annular enlargement. However, RV elongation with leaflet tethering is seen in patients who have secondary TR caused by pulmonary hypertension or myocardial disease.
• These patients with AF-related TR have rapid progression of TR severity and right-sided chamber dilation.
• In AF-related severe TR, quality of life and symptoms can be improved by surgical intervention for TR.
• Outcomes are better in patients undergoing intervention, without severe RV dysfunction or end-organ damage.

Surgical Methods

Annuloplasty

The principal surgical repair for secondary TR is tricuspid annuloplasty. The aim of tricuspid annuloplasty is to improve leaflet coaptation by correcting annular dilatation and restoring annular geometry. The two principle surgical methods are:

• Ring annuloplasty: It is regarded as the standard for surgical repair. The size of the tricuspid annulus is permanently fixed by implantation of a rigid or semi rigid prosthesis, undersized ring, and it is associated with a reduced incidence of late, recurrent tricuspid regurgitation.
• Suture annuloplasty: It is technically easy and can be done quickly. Also, compared with the ring annuloplasty, a prosthetic implant is not used with suture annuloplasty and the risk of postoperative conduction disturbances is lower.

The transthoracic echocardiography after tricuspid valve repair showed satisfactory leaflet coaptation (A) and repaired papillary muscle (B). Case courtesy by Han-Young Jin et al

Other methods:

• Adjunctive repair techniques: This may be necessary for augmentation of the effects of the ring annuloplasty in patients with marked leaflet tethering and right ventricular remodeling. The long-term outcomes and durability of these adjunctive techniques are not well established. Types of adjunctive repair techniques are listed in the table below.

Anterior leaflet augmentation using an autologous pericardial patch	''Clover'' technique	Double orifice valve technique
Helps improve leaflet coaptation while maintaining leaflet mobility	Approximates the free edges of the three leaflets, producing a clover-shaped valve It has also been used to treat selected patients with complex primary tricuspid regurgitation	Promising outcomes have been reported Done by passing two sutures from the middle of the anterior portion of the annulus to the septal portion of the annulus, forcing leaflet coaptation

• Tricuspid valve replacement
• The initial approach in tricuspid surgery is repair; however, replacement is done whenever the valve is badly diseased.
  • Bioprosthetic valves are currently favored, however, no significant hemodynamic difference between mechanical and biological valves was observed.
• Transcatheter therapies
  • The safety and feasibility of transcatheter therapies for treating severe tricuspid regurgitation are shown in the study:
  • Three types of transcatheter therapies have recently emerged for treating severe tricuspid regurgitation:
    1. Heterotopic caval transcatheter valve implantation
    2. Transcatheter tricuspid valve annuloplasty
    3. Coaptation device

• Transcatheter tricuspid valve replacement